Cargando…

SRC kinase-mediated signaling pathways and targeted therapies in breast cancer

Breast cancer (BC) has been ranked the most common malignant tumor throughout the world and is also a leading cause of cancer-related deaths among women. SRC family kinases (SFKs) belong to the non-receptor tyrosine kinase (nRTK) family, which has eleven members sharing similar structure and functio...

Descripción completa

Detalles Bibliográficos
Autores principales: Luo, Juan, Zou, Hailin, Guo, Yibo, Tong, Tongyu, Ye, Liping, Zhu, Chengming, Deng, Liang, Wang, Bo, Pan, Yihang, Li, Peng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9798727/
https://www.ncbi.nlm.nih.gov/pubmed/36581908
http://dx.doi.org/10.1186/s13058-022-01596-y
_version_ 1784860964837916672
author Luo, Juan
Zou, Hailin
Guo, Yibo
Tong, Tongyu
Ye, Liping
Zhu, Chengming
Deng, Liang
Wang, Bo
Pan, Yihang
Li, Peng
author_facet Luo, Juan
Zou, Hailin
Guo, Yibo
Tong, Tongyu
Ye, Liping
Zhu, Chengming
Deng, Liang
Wang, Bo
Pan, Yihang
Li, Peng
author_sort Luo, Juan
collection PubMed
description Breast cancer (BC) has been ranked the most common malignant tumor throughout the world and is also a leading cause of cancer-related deaths among women. SRC family kinases (SFKs) belong to the non-receptor tyrosine kinase (nRTK) family, which has eleven members sharing similar structure and function. Among them, SRC is the first identified proto-oncogene in mammalian cells. Oncogenic overexpression or activation of SRC has been revealed to play essential roles in multiple events of BC progression, including tumor initiation, growth, metastasis, drug resistance and stemness regulations. In this review, we will first give an overview of SRC kinase and SRC-relevant functions in various subtypes of BC and then systematically summarize SRC-mediated signaling transductions, with particular emphasis on SRC-mediated substrate phosphorylation in BC. Furthermore, we will discuss the progress of SRC-based targeted therapies in BC and the potential future direction.
format Online
Article
Text
id pubmed-9798727
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-97987272022-12-30 SRC kinase-mediated signaling pathways and targeted therapies in breast cancer Luo, Juan Zou, Hailin Guo, Yibo Tong, Tongyu Ye, Liping Zhu, Chengming Deng, Liang Wang, Bo Pan, Yihang Li, Peng Breast Cancer Res Review Breast cancer (BC) has been ranked the most common malignant tumor throughout the world and is also a leading cause of cancer-related deaths among women. SRC family kinases (SFKs) belong to the non-receptor tyrosine kinase (nRTK) family, which has eleven members sharing similar structure and function. Among them, SRC is the first identified proto-oncogene in mammalian cells. Oncogenic overexpression or activation of SRC has been revealed to play essential roles in multiple events of BC progression, including tumor initiation, growth, metastasis, drug resistance and stemness regulations. In this review, we will first give an overview of SRC kinase and SRC-relevant functions in various subtypes of BC and then systematically summarize SRC-mediated signaling transductions, with particular emphasis on SRC-mediated substrate phosphorylation in BC. Furthermore, we will discuss the progress of SRC-based targeted therapies in BC and the potential future direction. BioMed Central 2022-12-29 2022 /pmc/articles/PMC9798727/ /pubmed/36581908 http://dx.doi.org/10.1186/s13058-022-01596-y Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Review
Luo, Juan
Zou, Hailin
Guo, Yibo
Tong, Tongyu
Ye, Liping
Zhu, Chengming
Deng, Liang
Wang, Bo
Pan, Yihang
Li, Peng
SRC kinase-mediated signaling pathways and targeted therapies in breast cancer
title SRC kinase-mediated signaling pathways and targeted therapies in breast cancer
title_full SRC kinase-mediated signaling pathways and targeted therapies in breast cancer
title_fullStr SRC kinase-mediated signaling pathways and targeted therapies in breast cancer
title_full_unstemmed SRC kinase-mediated signaling pathways and targeted therapies in breast cancer
title_short SRC kinase-mediated signaling pathways and targeted therapies in breast cancer
title_sort src kinase-mediated signaling pathways and targeted therapies in breast cancer
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9798727/
https://www.ncbi.nlm.nih.gov/pubmed/36581908
http://dx.doi.org/10.1186/s13058-022-01596-y
work_keys_str_mv AT luojuan srckinasemediatedsignalingpathwaysandtargetedtherapiesinbreastcancer
AT zouhailin srckinasemediatedsignalingpathwaysandtargetedtherapiesinbreastcancer
AT guoyibo srckinasemediatedsignalingpathwaysandtargetedtherapiesinbreastcancer
AT tongtongyu srckinasemediatedsignalingpathwaysandtargetedtherapiesinbreastcancer
AT yeliping srckinasemediatedsignalingpathwaysandtargetedtherapiesinbreastcancer
AT zhuchengming srckinasemediatedsignalingpathwaysandtargetedtherapiesinbreastcancer
AT dengliang srckinasemediatedsignalingpathwaysandtargetedtherapiesinbreastcancer
AT wangbo srckinasemediatedsignalingpathwaysandtargetedtherapiesinbreastcancer
AT panyihang srckinasemediatedsignalingpathwaysandtargetedtherapiesinbreastcancer
AT lipeng srckinasemediatedsignalingpathwaysandtargetedtherapiesinbreastcancer